- Home
- EPSM vs MBRX Comparison
EPSM vs MBRX Comparison
Compare EPSM & MBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EPSM | MBRX |
|---|---|---|
| Founded | 2010 | 2015 |
| Country | China | United States |
| Employees | 17 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.0M | 16.1M |
| IPO Year | N/A | 2016 |
Fundamental Metrics
Financial Performance| Metric | EPSM | MBRX |
|---|---|---|
| Price | $1.27 | $2.29 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $61.00 |
| AVG Volume (30 Days) | 67.0K | ★ 516.1K |
| Earning Date | 04-29-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.83 | $0.26 |
| 52 Week High | $155.00 | $7.98 |
Technical Indicators
Market Signals| Indicator | EPSM | MBRX |
|---|---|---|
| Relative Strength Index (RSI) | 46.50 | 41.89 |
| Support Level | $1.04 | $2.12 |
| Resistance Level | $1.53 | $2.64 |
| Average True Range (ATR) | 0.12 | 0.26 |
| MACD | -0.01 | -0.07 |
| Stochastic Oscillator | 18.29 | 6.95 |
Price Performance
Historical ComparisonAbout EPSM Epsium Enterprise Limited Ordinary Shares
Epsium Enterprise Ltd is a holding company and conducts business through its subsidiaries. It is engaged in import trading and wholesale selling of beverages in Macau. The company imports and sells a range of beverages, alcoholic beverages, and a small quantity of tea and fruit juice. The alcoholic beverages it sells include Chinese liquor, French cognac, Scottish whiskey, fine wine, Champagne, and other miscellaneous beverage alcohols.
About MBRX Moleculin Biotech Inc.
Moleculin Biotech Inc is a late-stage pharmaceutical development company currently evaluating Annamycin, also known as L-Annamycin and by its generic name naxtarubicin. The company has two additional portfolios of technologies for hard-to-treat cancers and viruses with clinical and preclinical research funded by investigators at academic institutions. The Company operates in one reportable segment, which is the development and commercialization of drug products.